Astellas Pharma Inc v. Somerset Therap LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Astellas Pharma Inc. (Japan); Astellas US LLC (Delaware)
  • Defendant: Somerset Therapeutics, LLC (Delaware); Somerset Pharma, LLC (Delaware); Somerset Therapeutics Private Limited (India); Odin Pharmaceuticals, LLC (Delaware)
  • Plaintiff's Counsel: McCarter & English, LLP
• Case Identification: 1:26-cv-00872, D. Del., 07/16/2026
• Venue Allegations: Venue is alleged to be proper as several defendants are organized under the laws of Delaware and the foreign defendant may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's CRESEMBA® capsules constitutes an act of infringement of two patents covering stabilized pharmaceutical formulations.
• Technical Context: The technology involves pharmaceutical formulations designed to protect moisture-sensitive active ingredients, like the antifungal drug isavuconazonium sulfate, from degradation by using an internal drying agent.
• Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' submission of ANDA No. 221483 and a subsequent notice letter to Plaintiffs. The patents-in-suit are listed in the FDA's "Orange Book" as covering the CRESEMBA® product. The complaint asserts that Defendants' notice letter effectively concedes infringement by not providing non-infringement defenses.

Case Timeline

Date	Event
2006-09-25	Earliest Priority Date for '879 and '280 Patents
2015-03-06	FDA approves NDA for CRESEMBA® capsules
2019-02-19	U.S. Patent No. 10,206,879 Issues
2020-03-31	U.S. Patent No. 10,603,280 Issues
2023-12-08	FDA approves expanded indication for CRESEMBA®
2026-06-04	Defendants send Notice Letter regarding ANDA filing
2026-07-16	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,206,879 - Active Ingredient Containing Stabilised Solid Medicinal Forms and Methods for the Production Thereof

The Invention Explained

• Problem Addressed: The patent's background section describes the significant challenge of ensuring the chemical and physical stability of solid medicinal forms containing moisture-sensitive active ingredients. Water, present in both active ingredients and excipients, can cause degradation, discoloration, and loss of efficacy, while conventional drying methods are often problematic or ineffective ʼ879 Patent, col. 3:20-44
• The Patented Solution: The invention is a solid medicinal formulation that incorporates a specific, water-soluble "internal drying agent"-trimagnesium dicitrate-directly into the formulation with the moisture-sensitive drug. This agent is designed to have a high capacity to firmly bond with free water, thereby "drying" the formulation from within and protecting the active ingredient from hydrolysis ʼ879 Patent, abstract ʼ879 Patent, col. 4:26-33 The result is a stable product with a very low "relative equilibrium moisture content" ʼ879 Patent, col. 4:62-67
• Technical Importance: This approach provided a method to create stable, oral solid dosage forms for highly sensitive drugs that might otherwise be difficult to manufacture or have a short shelf life, avoiding costly processes like deep-freezing or production in ultra-low humidity environments ʼ879 Patent, col. 3:51-58

Key Claims at a Glance

• The complaint asserts infringement of Claim 1, and reserves the right to assert other claims Compl. ¶57 Compl. ¶60
• Independent Claim 1 of the '879 Patent requires:
  • A non-effervescent solid medicinal form comprising a hydroxypropylmethylcellulose (HPMC) capsule.
  • The capsule is filled with a filling comprising:
    • 30 to 40% by weight of a moisture-sensitive active ingredient (which is not trimagnesium dicitrate).
    • 20 to 50% by weight of trimagnesium dicitrate acting as a drying agent.
    • 5 to 30% by weight of microcrystalline cellulose.
  • The medicinal form exhibits a drying loss of 0.5 to 2.5% (measured at 120° C./30 min).
  • The medicinal form exhibits a relative equilibrium moisture of at most 15% (measured at 25° C.).

U.S. Patent No. 10,603,280 - Active Ingredient Containing Stabilised Solid Medicinal Forms and Methods for the Production Thereof

The Invention Explained

• Problem Addressed: As a continuation of the application leading to the '879 Patent, the '280 Patent addresses the same problem: the instability of moisture-sensitive active ingredients within solid pharmaceutical dosage forms due to the presence of water ʼ280 Patent, col. 3:20-30
• The Patented Solution: The patent discloses the same solution as the parent '879 Patent-the use of an internal, water-soluble drying agent like trimagnesium dicitrate mixed with the active ingredient to achieve a low relative equilibrium moisture and prevent degradation ʼ280 Patent, abstract ʼ280 Patent, col. 4:26-33
• Technical Importance: The technical importance is identical to that of the '879 Patent, relating to the enhanced stability and manufacturability of oral dosage forms for sensitive drugs ʼ280 Patent, col. 3:51-58

Key Claims at a Glance

• The complaint asserts infringement of Claim 1, and reserves the right to assert other claims Compl. ¶69 Compl. ¶72
• Independent Claim 1 of the '280 Patent requires:
  • A non-effervescent solid medicinal form comprising an HPMC capsule.
  • The capsule is filled with a filling comprising:
    • 20 to 40% by weight of a moisture-sensitive active ingredient (which is not trimagnesium dicitrate).
    • 20 to 50% by weight of trimagnesium dicitrate acting as a drying agent.
    • 5 to 30% by weight of microcrystalline cellulose.
  • The medicinal form exhibits a relative equilibrium moisture of at most 15% (measured at 25° C.).
• Analyst Note: Claim 1 of the '280 Patent is notably different from Claim 1 of the '879 Patent in two ways: it claims a broader range for the active ingredient (20-40% vs. 30-40%) and omits the specific "drying loss" limitation, relying solely on the "relative equilibrium moisture" property.

III. The Accused Instrumentality

Product Identification

• "Somerset's Generic Product," identified as a 186 mg isavuconazonium sulfate oral capsule for which Defendants submitted ANDA No. 221483 Compl. ¶15 Compl. ¶43

Functionality and Market Context

• The product is a generic version of Plaintiffs' CRESEMBA® capsules and seeks FDA approval for the same indications: treatment of invasive aspergillosis and invasive mucormycosis Compl. ¶15 Compl. ¶45
• The complaint alleges the generic product will be a "non-effervescent solid medicinal form[] comprising HPMC capsules filled with a moisture-sensitive active ingredient (isavuconazonium sulfate), trimagnesium dicitrate acting as a drying agent... and microcrystalline cellulose" Compl. ¶60 Compl. ¶72
• A chemical structure diagram illustrates the active ingredient, isavuconazonium sulfate Compl. ¶35, p. 9
• The complaint alleges that if approved, the generic product will be manufactured, marketed, and sold throughout the United States, directly competing with Plaintiffs' branded product Compl. ¶14 Compl. ¶52

IV. Analysis of Infringement Allegations

'879 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A non-effervescent solid medicinal form comprising a hydroxypropylmethylcellulose (HPMC) capsule filled with a capsule filling	The generic product is alleged to be a non-effervescent solid medicinal form comprising an HPMC capsule.	¶60	col. 6:49-54
comprising: a. 30 to 40% by weight of a moisture-sensitive active ingredient...	The capsule filling is alleged to contain the moisture-sensitive active ingredient isavuconazonium sulfate.	¶60	col. 5:11-15
b. 20 to 50% by weight of trimagnesium dicitrate acting as a drying agent that stabilizes the moisture sensitive agent against hydrolysis during storage	The capsule filling is alleged to contain trimagnesium dicitrate acting as a drying agent.	¶60	col. 4:15-19
and c. 5 to 30% by weight of a microcrystalline cellulose	The capsule filling is alleged to contain microcrystalline cellulose.	¶60	col. 7:1-12
wherein said medicinal form exhibits a drying loss, measured at 120° C./30 min, of 0.5 to 2.5% and a relative equilibrium moisture, measured at 25° C., of at most 15%.	The generic product will allegedly exhibit a drying loss and relative equilibrium moisture within the claimed scope.	¶60	col. 4:38-54; col. 5:23-38

'280 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A non-effervescent solid medicinal form comprising a hydroxypropylmethylcellulose (HPMC) capsule filled with a capsule filling	The generic product is alleged to be a non-effervescent solid medicinal form comprising an HPMC capsule.	¶72	col. 7:51-55
comprising: a. 20 to 40% by weight of a moisture-sensitive active ingredient...	The capsule filling is alleged to contain the moisture-sensitive active ingredient isavuconazonium sulfate.	¶72	col. 5:11-15
b. 20 to 50% by weight of trimagnesium dicitrate acting as a drying agent that stabilizes the moisture sensitive agent against hydrolysis during storage	The capsule filling is alleged to contain trimagnesium dicitrate acting as a drying agent.	¶72	col. 4:15-19
and c. 5 to 30% by weight of a microcrystalline cellulose	The capsule filling is alleged to contain microcrystalline cellulose.	¶72	col. 7:1-12
wherein said medicinal form exhibits a relative equilibrium moisture, measured at 25° C., of at most 15%.	The generic product will allegedly exhibit a relative equilibrium moisture within the claimed scope.	¶72	col. 5:23-38

Identified Points of Contention

• Factual Questions: A central question of fact will be whether the specific formulation detailed in Defendants' ANDA actually meets all quantitative limitations of the asserted claims. The complaint alleges Defendants' notice letter "does not dispute" this and "concede[s]" that the product meets the limitations Compl. ¶48 Compl. ¶59 Compl. ¶71 This framing suggests Plaintiffs' primary theory is one of concession, but the court's analysis will likely require factual proof regarding the generic product's composition and properties.
• Technical Questions: The case may raise technical questions regarding the measurement methodologies for "drying loss" and "relative equilibrium moisture." The court will need to determine if Defendants' product, when tested according to the specific procedures outlined in the patent specification, falls within the claimed ranges.

V. Key Claim Terms for Construction

• The Term: "relative equilibrium moisture"

• Context and Importance: This functional limitation is present in the independent claims of both patents and is central to the invention's stated purpose of ensuring stability. The infringement analysis will depend entirely on whether the accused product exhibits this property, making its definition critical.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party could argue the term should be given its plain and ordinary meaning as understood by a person of ordinary skill in the art of pharmaceutical formulation. The patent describes it generally as the "value of the relative humidity in which a hygroscopic product can be stored without a net moisture exchange" ʼ879 Patent, col. 5:8-12
  • Evidence for a Narrower Interpretation: The specification provides a highly specific method for determining this value, stating that "the device HygroLab having the AWVC measuring cell of Rotronic company... is used," and that "[t]he measurement takes place at 25° C." ʼ879 Patent, col. 5:29-37 A party could argue this disclosure defines the term and limits its scope to measurements performed using this specific apparatus and protocol.

• The Term: "drying agent that stabilizes the moisture sensitive agent against hydrolysis"

• Context and Importance: This term defines the function of the trimagnesium dicitrate. A dispute could arise over whether the trimagnesium dicitrate in the accused product performs this specific stabilizing function, as opposed to being present for a different purpose (e.g., as a simple filler or buffer).

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent states that suitable drying agents are those that can "firmly bond water" and have a "high drying capacity" ʼ879 Patent, col. 4:28-30 A party might argue that if trimagnesium dicitrate is present and the final product is stable against hydrolysis, this limitation is met.
  • Evidence for a Narrower Interpretation: The patent contrasts the invention with prior art methods and emphasizes that the drying agent actively "extracts water e.g. from the granule constituents" ʼ879 Patent, col. 3:66-67 A party could argue this requires proof that the trimagnesium dicitrate is the principal cause of stability via this specific water-bonding mechanism.

VI. Other Allegations

• Indirect Infringement: The complaint's primary counts are for infringement under 35 U.S.C. § 271(e)(2) based on the ANDA submission Compl. ¶56 Compl. ¶68 The prayer for relief also seeks a judgment of infringement under § 271(a) for future commercial activity Prayer ¶B The complaint alleges that Defendants know or should know that their commercial activities will infringe, which lays the factual predicate for induced infringement upon product launch Compl. ¶64 Compl. ¶76
• Willful Infringement: The complaint alleges Defendants were aware of the patents through their listing in the FDA's Orange Book and their own Notice Letter Compl. ¶62 Compl. ¶74 It further alleges that Defendants' invalidity positions are devoid of a good faith basis and that the case is "exceptional," seeking enhanced damages and attorney fees Compl. ¶65 Compl. ¶77 Prayer ¶G

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue will be one of evidentiary proof versus pleading: The complaint alleges that Defendants have conceded infringement by failing to raise non-infringement arguments in their notice letter. A key question is whether the court will accept this theory or require Plaintiffs to affirmatively prove, with technical evidence, that the formulation detailed in the confidential ANDA meets every quantitative and functional limitation of the asserted claims.
• A second core issue may be one of claim scope defined by measurement: The case could turn on the construction of "relative equilibrium moisture." A central question for the court will be whether this term is limited to the specific measurement device and protocol disclosed in the specification. A narrow construction could provide a path for non-infringement if the accused product's properties fall outside the claimed range when measured by a different, but arguably standard, method.